feed,title,long_url,short_url
Benzinga,Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer,https://benzinga.com/general/biotech/22/02/25634534/aveo-says-tivozanib-patients-up-to-5x-more-likely-to-experience-long-term-pfs-vs-nexavar-in-kidne,https://bit.ly/3GOMJTl
Benzinga,"Voyager Digital Reports Best Quarter Ever, Doubling Of Revenue",https://benzinga.com/news/earnings/22/02/25632444/voyager-digital-reports-best-quarter-ever-doubling-of-revenue,https://bit.ly/3sGFWGq
